NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

毒蕈鹼性乙醯膽鹼受體M4 (CHRM4):開發中產品分析

Muscarinic Acetylcholine Receptor M4 - Pipeline Review, H2 2020

出版商 Global Markets Direct 商品編碼 520778
出版日期 內容資訊 英文 86 Pages
訂單完成後即時交付
價格
毒蕈鹼性乙醯膽鹼受體M4 (CHRM4):開發中產品分析 Muscarinic Acetylcholine Receptor M4 - Pipeline Review, H2 2020
出版日期: 2020年10月30日內容資訊: 英文 86 Pages
簡介

本報告提供以毒蕈鹼性乙醯膽鹼受體M4 (CHRM4)為標的之治療藥開發平台現狀及最新更新之各開發階段比較分析,提供涵括了最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

毒蕈鹼性乙醯膽鹼受體M4 (CHRM4);概要

毒蕈鹼性乙醯膽鹼受體M4 (CHRM4);治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀
  • 企業開發中的產品

治療藥的評估

  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Anavex Life Sciences Corp
  • AstraZeneca Plc
  • Heptares Therapeutics Ltd
  • Karuna Pharmaceuticals Inc
  • NeuroHealing Pharmaceuticals Inc
  • 大日本住友製藥

藥物簡介

暫停中的產品

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2607TDB

Summary:

According to the recently published report 'Muscarinic Acetylcholine Receptor M4 - Pipeline Review, H2 2020'; Muscarinic Acetylcholine Receptor M4 (CHRM4) pipeline Target constitutes close to 18 molecules.

Muscarinic Acetylcholine Receptor M4 (CHRM4) - Muscarinic acetylcholine receptor M4 or cholinergic receptor muscarinic 4 (CHRM4) is a protein encoded by the CHRM4 gene. It mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins.

The report 'Muscarinic Acetylcholine Receptor M4 - Pipeline Review, H2 2020' outlays comprehensive information on the Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 3, 9 and 2 respectively. Report covers products from therapy areas Central Nervous System, Genetic Disorders, Mouth and Dental Disorders and Ophthalmology which include indications Alzheimer's Disease, Schizophrenia, Psychosis, Parkinson's Disease, Amnesia, Amyotrophic Lateral Sclerosis, Angelman Syndrome, Anxiety Disorders, Cognitive Disorders, Cognitive Impairment, Cognitive Impairment Associated With Schizophrenia (CIAS), Depression, Drug-Induced Dyskinesia, Fragile X Syndrome, Infantile Spasm (West Syndrome), Movement Disorders, Multiple Sclerosis, Neurology, Presbyopia, Rett Syndrome, Sialorrhoea and Tuberous Sclerosis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Muscarinic Acetylcholine Receptor M4 (CHRM4)
  • The report reviews Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Muscarinic Acetylcholine Receptor M4 (CHRM4) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Muscarinic Acetylcholine Receptor M4 (CHRM4)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Muscarinic Acetylcholine Receptor M4 (CHRM4) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Muscarinic Acetylcholine Receptor M4 (CHRM4) - Overview
  • Muscarinic Acetylcholine Receptor M4 (CHRM4) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Muscarinic Acetylcholine Receptor M4 (CHRM4) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Muscarinic Acetylcholine Receptor M4 (CHRM4) - Companies Involved in Therapeutics Development
  • Anavex Life Sciences Corp
  • AstraZeneca Plc
  • Cerevel Therapeutics LLC
  • Karuna Therapeutics Inc
  • Lan Sheng Biomedicine Suzhou Co Ltd
  • NeuroHealing Pharmaceuticals Inc
  • NeuroSolis Inc
  • Presbyopia Therapies LLC
  • Sosei Heptares
  • Suven Life Sciences Ltd
  • Muscarinic Acetylcholine Receptor M4 (CHRM4) - Drug Profiles
  • (aceclidine + tropicamide) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (trospium chloride + xanomeline) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • blarcamesine hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CVL-231 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Drug to Agonize CHRM4 for Drug-Induced Dyskinesia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HTL-0016878 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LS-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NSX-0527 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NSX-0527f - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NSX-0559 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NSX-0559f - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Agonize M1 and M4 Muscarinic Acetylcholine Receptors for Psychosis and Cognitive Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Agonize Muscarinic Acetylcholine Receptor 4 for Psychosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Agonize Muscarinic M1 and M4 Receptors for Psychosis and Neurologic Diseases - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tropicamide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VU-0467154 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VU-6000918 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • VU-6001852 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Muscarinic Acetylcholine Receptor M4 (CHRM4) - Dormant Products
  • Muscarinic Acetylcholine Receptor M4 (CHRM4) - Discontinued Products
  • Muscarinic Acetylcholine Receptor M4 (CHRM4) - Product Development Milestones
  • Featured News & Press Releases
  • Sep 10, 2020: Anavex Life Sciences announces completion of ANAVEX2-73 (blarcamesine) U.S. Phase 2 Rett Syndrome clinical trial
  • Aug 19, 2020: Anavex Life Sciences announces commitment for Financial Investment by Shake It Up Foundation for Parkinson's Research for clinical trial of ANAVEX®2-73 (Blarcamesine) in patients with Parkinson's disease
  • Aug 05, 2020: Anavex Life Sciences receives TGA special access scheme approval for ANAVEX2-73 (blarcamesine) for Alzheimer's disease patients
  • Aug 03, 2020: Karuna Therapeutics announces topline data from phase 1b trial evaluating KarXT on experimentally induced pain in healthy volunteers
  • Jul 02, 2020: Anavex starts dosing patients in Rett syndrome trial
  • Jul 01, 2020: Anavex Life Sciences announces first patient dosed in EXCELLENCE Phase 2/3 clinical trial of ANAVEX®2-73 (Blarcamesine) in patients with Rett Syndrome
  • Jun 23, 2020: Karuna Therapeutics announces positive outcome of end-of-phase 2 meeting with the FDA for KarXT for the treatment of acute psychosis in patients with schizophrenia
  • Jun 16, 2020: Anavex Life Sciences announces exceeding of enrollment target for the ANAVEX 2-73 (blarcamesine) U.S. phase 2 Rett Syndrome clinical trial
  • Jun 04, 2020: Anavex Life Sciences receives regulatory approval from Health Canada and UK MHRA expanding phase 2b/3 ANAVEX2-73 (blarcamesine) into multinational clinical trial for Alzheimer's disease
  • May 27, 2020: Karuna Therapeutics to present additional data from the phase 2 clinical trial of KarXT for the treatment of psychosis in patients with schizophrenia at the American Society of Clinical Psychopharmacology 2020 Annual Meeting
  • Apr 23, 2020: Anavex Life Sciences announces publication of clinical data for ANAVEX2-73 (blarcamesine) in Alzheimer's Disease
  • Feb 24, 2020: Anavex Life Sciences announces publication of foundational data for ANAVEX2-73 (blarcamesine) in multiple sclerosis (MS)
  • Feb 03, 2020: Anavex Life Sciences announces Fast Track Designation granted by U.S. FDA for ANAVEX2-73 (blarcamesine) clinical development program for the treatment of Rett Syndrome
  • Jan 27, 2020: Anavex Life Sciences announces achievement of enrollment target for the ANAVEX2-73 (blarcamesine) phase 2 Parkinson's Disease Dementia (PDD) clinical trial
  • Jan 08, 2020: Anavex Life Sciences issued new U.S. patent for ANAVEX2-73 treatment of Neurodevelopmental Disorders including Rett Syndrome and Multiple Sclerosis
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

List of Tables

  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Indications, H2 2020
  • Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020 (Contd..1), H2 2020
  • Products under Development by Companies, H2 2020 (Contd..2), H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Pipeline by Anavex Life Sciences Corp, H2 2020
  • Pipeline by AstraZeneca Plc, H2 2020
  • Pipeline by Cerevel Therapeutics LLC, H2 2020
  • Pipeline by Karuna Therapeutics Inc, H2 2020
  • Pipeline by Lan Sheng Biomedicine Suzhou Co Ltd, H2 2020
  • Pipeline by NeuroHealing Pharmaceuticals Inc, H2 2020
  • Pipeline by NeuroSolis Inc, H2 2020
  • Pipeline by Presbyopia Therapies LLC, H2 2020
  • Pipeline by Sosei Heptares, H2 2020
  • Pipeline by Suven Life Sciences Ltd, H2 2020
  • Dormant Projects, H2 2020
  • Discontinued Products, H2 2020

List of Figures

List of Figures

  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Top 10 Indications, H2 2020
  • Number of Products by Mechanism of Actions, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020